Infliximab vs Ustekinumab in Biologic Naive Crohn's Disease
- PMID: 33991689
- DOI: 10.1016/j.cgh.2021.05.013
Infliximab vs Ustekinumab in Biologic Naive Crohn's Disease
Comment in
-
Reply.Clin Gastroenterol Hepatol. 2022 May;20(5):e1216-e1217. doi: 10.1016/j.cgh.2021.05.051. Epub 2021 May 28. Clin Gastroenterol Hepatol. 2022. PMID: 34058410 No abstract available.
Comment on
-
Comparative Efficacy and Rapidity of Action for Infliximab vs Ustekinumab in Biologic Naïve Crohn's Disease.Clin Gastroenterol Hepatol. 2022 Jul;20(7):1579-1587.e2. doi: 10.1016/j.cgh.2021.04.006. Epub 2021 Apr 7. Clin Gastroenterol Hepatol. 2022. PMID: 33838348 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical